国内染色体核型分析领军企业将赴港上市

Core Viewpoint - Hangzhou Deshi Biotechnology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, marking a significant step in its journey towards going public after receiving regulatory approval [1][2]. Group 1: Company Overview - Deshi Biotechnology focuses on chromosome karyotype analysis, a classic method for diagnosing major diseases related to chromosomal abnormalities, which include birth defects, infertility, and hematological malignancies [1]. - The traditional karyotype analysis method relies heavily on manual operations, resulting in an average accuracy rate of only about 50% and a reporting cycle of approximately 30 days [1]. Group 2: Market Position and Innovation - The automated karyotype analysis market is dominated by international giants like Carl Zeiss and Leica, which hold over 95% of the market share [2]. - In response to the significant market demand and the lack of domestic equipment, Deshi Biotechnology has pursued an independent innovation path, developing intelligent devices and systems based on the iMedImage platform model [2]. - The company has created a highly integrated automated cell laboratory pipeline that covers four key stages of chromosome karyotype analysis: cell harvesting, slide preparation, image acquisition, and intelligent analysis, achieving full-process automation and standardization [2]. - By 2024, Deshi Biotechnology is projected to capture a market share of 30.6% in China's chromosome karyotype analysis sector, surpassing international competitors and marking a leap forward for domestic manufacturers [2].